Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life

Results from a noninterventional study

Ludger Klimek, Claus Bachert, Ralph Mösges, Ullrich Munzel, David Price, J Christian Virchow, Ulrich Wahn, Jean Bousquet

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) has been well established in controlled clinical trials. This study was designed to assess the use of MP29-02 and its effectiveness in routine clinical practice. This was a German multicenter, prospective, noninterventional study, including 1781 allergic rhinitis (AR) patients. Eligible patients (i.e., acute AR symptoms and visual analog scale [VAS] score >50 mm) were included, assigned MP29-02 at baseline, and reassessed after ∼14 days. Patients assessed symptom control using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP29-02 use, on days 0, 1, 3, and 7 and after ∼ 14 days. Patients' perceived levels of disease control were assessed on day 3. The Youden index determined patient-reported VAS score cutoffs on day 3 for "well controlled" and "partly controlled." MP29-02 reduced the VAS score from 75.4 mm (SD = 17.2) at baseline to 21.3 mm (SD = 18.3) by the last visit, a shift of 54.1 mm (SD = 24.6). One in every two patients felt their symptoms were well controlled at day 3. This perception of well-controlled symptoms at day 3 corresponded to an optimal VAS cutoff of 36 mm. On average, patients treated with MP29-02 crossed this well-controlled VAS cutoff by last visit. Similar results were found in adolescents, adults, and older adults, in those with perennial AR (PAR), seasonal AR (SAR), or PAR + SAR and in those with more and less severe disease. MP29-02 provides effective and rapid symptom control across all age groups in a real-life setting with responder rates higher than those observed in controlled clinical trials, supporting MP29-02's position as the drug of choice for the treatment for AR.

Original languageEnglish
Pages (from-to)40-47
Number of pages8
JournalAllergy and Asthma Proceedings
Volume36
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015

Fingerprint

Visual Analog Scale
Controlled Clinical Trials
Therapeutics
azelastine
Seasonal Allergic Rhinitis
MP29-02
Allergic Rhinitis
Age Groups
Prospective Studies
Pharmaceutical Preparations

Keywords

  • allergic rhinitis
  • dymista
  • MP29-02
  • azelastine
  • control
  • effectiveness
  • fluticasone
  • intranasal
  • real-life
  • visual analog scale

Cite this

Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life : Results from a noninterventional study. / Klimek, Ludger; Bachert, Claus; Mösges, Ralph; Munzel, Ullrich; Price, David; Virchow, J Christian; Wahn, Ulrich; Bousquet, Jean.

In: Allergy and Asthma Proceedings, Vol. 36, No. 1, 01.01.2015, p. 40-47.

Research output: Contribution to journalArticle

Klimek, Ludger ; Bachert, Claus ; Mösges, Ralph ; Munzel, Ullrich ; Price, David ; Virchow, J Christian ; Wahn, Ulrich ; Bousquet, Jean. / Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life : Results from a noninterventional study. In: Allergy and Asthma Proceedings. 2015 ; Vol. 36, No. 1. pp. 40-47.
@article{d772fbf0e425457f858f59f5f2c7c93b,
title = "Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: Results from a noninterventional study",
abstract = "The efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) has been well established in controlled clinical trials. This study was designed to assess the use of MP29-02 and its effectiveness in routine clinical practice. This was a German multicenter, prospective, noninterventional study, including 1781 allergic rhinitis (AR) patients. Eligible patients (i.e., acute AR symptoms and visual analog scale [VAS] score >50 mm) were included, assigned MP29-02 at baseline, and reassessed after ∼14 days. Patients assessed symptom control using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP29-02 use, on days 0, 1, 3, and 7 and after ∼ 14 days. Patients' perceived levels of disease control were assessed on day 3. The Youden index determined patient-reported VAS score cutoffs on day 3 for {"}well controlled{"} and {"}partly controlled.{"} MP29-02 reduced the VAS score from 75.4 mm (SD = 17.2) at baseline to 21.3 mm (SD = 18.3) by the last visit, a shift of 54.1 mm (SD = 24.6). One in every two patients felt their symptoms were well controlled at day 3. This perception of well-controlled symptoms at day 3 corresponded to an optimal VAS cutoff of 36 mm. On average, patients treated with MP29-02 crossed this well-controlled VAS cutoff by last visit. Similar results were found in adolescents, adults, and older adults, in those with perennial AR (PAR), seasonal AR (SAR), or PAR + SAR and in those with more and less severe disease. MP29-02 provides effective and rapid symptom control across all age groups in a real-life setting with responder rates higher than those observed in controlled clinical trials, supporting MP29-02's position as the drug of choice for the treatment for AR.",
keywords = "allergic rhinitis, dymista, MP29-02, azelastine, control, effectiveness, fluticasone, intranasal, real-life, visual analog scale",
author = "Ludger Klimek and Claus Bachert and Ralph M{\"o}sges and Ullrich Munzel and David Price and Virchow, {J Christian} and Ulrich Wahn and Jean Bousquet",
note = "ACKNOWLEDGMENTS The authors thank Ruth Murray, Ph.D., for assistance with drafting, editing, and reviewing this article.",
year = "2015",
month = "1",
day = "1",
doi = "10.2500/aap.2015.36.3823",
language = "English",
volume = "36",
pages = "40--47",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life

T2 - Results from a noninterventional study

AU - Klimek, Ludger

AU - Bachert, Claus

AU - Mösges, Ralph

AU - Munzel, Ullrich

AU - Price, David

AU - Virchow, J Christian

AU - Wahn, Ulrich

AU - Bousquet, Jean

N1 - ACKNOWLEDGMENTS The authors thank Ruth Murray, Ph.D., for assistance with drafting, editing, and reviewing this article.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) has been well established in controlled clinical trials. This study was designed to assess the use of MP29-02 and its effectiveness in routine clinical practice. This was a German multicenter, prospective, noninterventional study, including 1781 allergic rhinitis (AR) patients. Eligible patients (i.e., acute AR symptoms and visual analog scale [VAS] score >50 mm) were included, assigned MP29-02 at baseline, and reassessed after ∼14 days. Patients assessed symptom control using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP29-02 use, on days 0, 1, 3, and 7 and after ∼ 14 days. Patients' perceived levels of disease control were assessed on day 3. The Youden index determined patient-reported VAS score cutoffs on day 3 for "well controlled" and "partly controlled." MP29-02 reduced the VAS score from 75.4 mm (SD = 17.2) at baseline to 21.3 mm (SD = 18.3) by the last visit, a shift of 54.1 mm (SD = 24.6). One in every two patients felt their symptoms were well controlled at day 3. This perception of well-controlled symptoms at day 3 corresponded to an optimal VAS cutoff of 36 mm. On average, patients treated with MP29-02 crossed this well-controlled VAS cutoff by last visit. Similar results were found in adolescents, adults, and older adults, in those with perennial AR (PAR), seasonal AR (SAR), or PAR + SAR and in those with more and less severe disease. MP29-02 provides effective and rapid symptom control across all age groups in a real-life setting with responder rates higher than those observed in controlled clinical trials, supporting MP29-02's position as the drug of choice for the treatment for AR.

AB - The efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) has been well established in controlled clinical trials. This study was designed to assess the use of MP29-02 and its effectiveness in routine clinical practice. This was a German multicenter, prospective, noninterventional study, including 1781 allergic rhinitis (AR) patients. Eligible patients (i.e., acute AR symptoms and visual analog scale [VAS] score >50 mm) were included, assigned MP29-02 at baseline, and reassessed after ∼14 days. Patients assessed symptom control using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP29-02 use, on days 0, 1, 3, and 7 and after ∼ 14 days. Patients' perceived levels of disease control were assessed on day 3. The Youden index determined patient-reported VAS score cutoffs on day 3 for "well controlled" and "partly controlled." MP29-02 reduced the VAS score from 75.4 mm (SD = 17.2) at baseline to 21.3 mm (SD = 18.3) by the last visit, a shift of 54.1 mm (SD = 24.6). One in every two patients felt their symptoms were well controlled at day 3. This perception of well-controlled symptoms at day 3 corresponded to an optimal VAS cutoff of 36 mm. On average, patients treated with MP29-02 crossed this well-controlled VAS cutoff by last visit. Similar results were found in adolescents, adults, and older adults, in those with perennial AR (PAR), seasonal AR (SAR), or PAR + SAR and in those with more and less severe disease. MP29-02 provides effective and rapid symptom control across all age groups in a real-life setting with responder rates higher than those observed in controlled clinical trials, supporting MP29-02's position as the drug of choice for the treatment for AR.

KW - allergic rhinitis

KW - dymista

KW - MP29-02

KW - azelastine

KW - control

KW - effectiveness

KW - fluticasone

KW - intranasal

KW - real-life

KW - visual analog scale

U2 - 10.2500/aap.2015.36.3823

DO - 10.2500/aap.2015.36.3823

M3 - Article

VL - 36

SP - 40

EP - 47

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 1

ER -